Get started
Author

Marta Pisini

Observed names: M Pisini, M. Pisini
OpenAlex ID: A5008958385
Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013
2018 · Kari Remes, Pekka Anttila, et al. · PLoS ONE · 32
PDF
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)
2019 · Meletios A. Dimopoulos, Michele Cavo, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 7
A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-αand ribavirin in patients infected with genotype 1 Hepatitis C virus
2015 · Vanessa Taieb, Maud Pacou, et al. · Journal of Medical Economics · 6
PDF
Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology
2015 · Suzy Van Sanden, Marta Pisini, et al. · Current Medical Research and Opinion · 4
Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder Cancer
2025 · Félix Guerrero-Ramos, Carsten Schwenke, et al. · European Urology Oncology · 3
A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)
2019 · Thierry Facon, Jesús San-Miguel, et al. · Blood · 3
Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis
2018 · Jesus F San-Miguel, Thierry Facon, et al. · Blood · 3
Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service
2017 · Kirsten Westerhout, Walter Bouwmeester, et al. · ClinicoEconomics and Outcomes Research · 3
PDF
Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape
2021 · Fredrik Borgsten, Xenia Gatopoulou, et al. · European Journal Of Haematology · 1
PDF
Ps1395 Comparative Effectiveness of Front-line Treatments for Patients With Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
2019 · T. Facon, J. San-Miguel, et al. · HemaSphere · 1
Pcn247 Progression-free Survival (pfs) With Daratumumab- Bortezomib-melphalan-prednisone (d-vmp) Combination Therapy and Alternative Treatments for Patients With Newly-diagnosed Multiple Myeloma (mm) Ineligible for Stem Cell Transplantation (asct): a Parametric Network Meta-analysis (pnma)
2019 · S. van Beekhuizen, M. Pisini, et al. · Value in Health · 1
A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide
2018 · Meletios A Dimopoulos, Michele Cavo, et al. · Blood · 1
Psy17 - Treatment Regimens for Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: a Systematic Literature Review and Network Meta-analysis
2018 · J. San-Miguel, T. Facon, et al. · Value in Health · 1
RWD24 Association of Recurrences With Healthcare Resource Utilization in High-Risk Non-Muscle Invasive Bladder Cancer Patients Across Europe: A Real-World Survey
2025 · Siobhán Mulhern-Haughey, Farah Hodeib, et al. · Value in Health
Health-related quality of life in muscle invasive bladder cancer patients receiving radical surgery versus those who do not: A real-world survey
2025 · J.W.F. Catto, F. Hodeib, et al. · European Urology Open Science
P099 – Treatment patterns in muscle invasive bladder cancer patients across Europe and the United Kingdom: A real-world survey
2025 · M. Roumiguie, F. Hodeib, et al. · European Urology
P250 Treatment patterns in treatment naïve high-risk non-muscle invasive bladder cancer across EU4 + UK: A real-world study
2024 · G. Simone, S. Darbas, et al. · European Urology Open Science
PCR182 Patient Preferences for Tumor-Agnostic Therapies: Qualitative Insights and Challenges
2023 · C. Metekohy, M. Pisini, et al. · Value in Health
PDF
HTA101 Diagnostic Testing (DTx) Costs: A Hidden Barrier to Accessing Histology-Independent Technologies (HITs)
2022 · S Palmer, A Walker, et al. · Value in Health
PDF
Healthcare Resource Utilization and Sickness Absence in Newly Diagnosed Multiple Myeloma Patients in Sweden: Trends in a Changing Treatment Landscape
2020 · Fredrik Borgsten, Xenia Gatopoulou, et al. · Blood
Pcn245 Applicability of a Response-based Model in Newly-diagnosed Transplant-ineligible Multiple Myeloma
2019 · Y. Hu, S. van Beekhuizen, et al. · Value in Health
Psy46 - a Dynamic Approach for Budget Impact Analysis (bia) in Oncology – the Case of Novel Treatment Combinations for Frontline Transplant-ineligible Newly Diagnosed Multiple Myeloma (tie Ndmm)
2018 · H. Le, F. Pan, et al. · Value in Health
Testing for Ns5a Resistance in Order to Optimize Antiviral Therapy With Simeprevir And Sofosbuvir 12 Weeks Appears Cost-Effective in Non-Cirrhotic Genotype 1 Hepatitis C Virus Treatment Experienced Patients
2015 · KY Westerhout, W Bouwmeester, et al. · Value in Health
Real-World Hepatitis C Treatment Strategies in Denmark
2015 · J Jalbert, M Pisini, et al. · Value in Health
PDF
P739 Risk Factors and Treatment Outcomes in Genotype 1 and Genotype 4 Hepatitis C Infected Patients From a Real World Data Analysis in Europe
2014 · C. Moreno, Y. Horsmans, et al. · Journal of Hepatology
Works count: 25
Citation count: 66
H-index: 4
I10-index: 1
Year
Topic
Type